Page 133 - Eceptor News Today

Checkpoint inhibitors have become important tools in the cancer-fighting arsenal. By blocking proteins that normally restrain the immune response, these drugs can help the immune system destroy cancer cells.

In this interview, News-Medical speaks to Professor Jun Huang about CAR T-cell therapy and its future as a potential treatment for cancer or HIV.

Researchers investigated the impact of amino acid substitutions of SARS-CoV-2 Omicron on spike protein function, processing, and neutralization susceptibility.

Fighting cancer and chronic disease is tiring work for the immune system. When T cells are engaged in this kind of lengthy battle, they can become exhausted, or unable to function properly.

ENSEMBLE data was used to evaluate three immune markers as correlates of protection following a single dose of Ad26.COV2.S vaccine.

Researchers describe a 16-month-old case of SARS-CoV-2 infection in an immunocompromised individual.

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor T cell therapies for cancer, today announced the... | April 19, 2022

Researchers assess the Arg-Gly-Asp (RGD) motif-mediated binding of the SARS-CoV-2 RBD and integrin receptors.

Researchers found six monoclonal antibodies binding to the spike proteins of all human coronaviruses.

Researchers reviewed the antibody resistance exhibited by SARS-CoV-2 variants.